Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
DACTINOMYCIN
Lundbeck Pharmaceuticals Ireland
0.5 Milligram
Pdr for Soln for Injection
2006-09-01
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Cosmegen ® Lyovac* 500 micrograms Powder for Solution for Injection. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each vial provides 500 micrograms Dactinomycin. When reconstituted as directed, the resulting solution will contain 500 micrograms Dactinomycin per mL. For a full list of excipients, see Section 6.1. 3 PHARMACEUTICAL FORM Powder for solution for injection. A yellow/orange lyophilised powder. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS ‘Cosmegen’ is a cytotoxic, antineoplastic antibiotic with immunosuppressant properties. ‘Cosmegen’, as part of a combination chemotherapy and/or multi-modality treatment regimen, is indicated for the treatment of Wilms’ tumor, childhood rhabdomyosarcoma, Ewing’s sarcoma, and metastatic nonseminomatous testicular cancer. ‘Cosmegen’ is indicated as a single agent, or as part of a combination chemotherapy regimen, for the treatment of gestational trophoblastic neoplasia. ‘Cosmegen’, as a component of regional perfusion in combination with melphalan, is indicated for the treatment of locally recurrent or locoregionally metastatic melanoma. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Toxic reactions due to ‘Cosmegen’ are frequent and may be severe (see 4.8 ‘Undesirable effects’), thus limiting the amount that may be given in many cases. However, the severity of toxicity varies markedly and is only partly dependent on the dosage used. The dosage of ‘Cosmegen’ will vary with the tolerance of the patient, the size and location of the neoplasm, and the use of other forms of therapy. It may be necessary to reduce the usual dosage suggested below when additional chemotherapy or radiation therapy is used concurrently, or has been employed previously. The dosag Read the complete document